The efficacy of selective NLRP3 inhibitors for the treatment of NLRP3-related inflammatory diseases, such as neurodegenerative diseases, gouty arthritis, CAPS and metabolic disease, has been widely demonstrated in several preclinical models and ex-vivo systems [17,50,51,59,60]. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.